Argenx SE (ARGX) | Stock Overview & Key Data
Argenx SE | Large-cap | Healthcare
Argenx SE | Large-cap | Healthcare
Argenx SE Performance Comparison
Stock Range
Today's Range
Low: €622.80
High: €630.20
on September 23, 2025
52 Week Range
Low: €456.30
High: €664.80
on September 24, 2024
on September 10, 2025
All-Time High: €664.80 on September 10, 2025
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€38.4B
EPS
16.69
P/E Ratio (TTM)
37.82
Forward P/E
77.45
P/B Ratio
6.33
PEG Ratio
77.45
Div. Yield
N/A
ROE
24.72%
Beta
0.001
Debt to Equity
0.71
Financial Highlights
Profitability
Gross Margin
88.32%
Operating Margin
21.08%
Profit Margin
41.03%
Returns and Earnings
Return on Assets (TTM)
4.83%
Return on Equity (TTM)
24.72%
EBITDA
€502.6M
Net Income (TTM)
€1.1B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€51.36
Quarterly Revenue Growth (YoY)
97.60%
Quarterly Earnings Growth (YoY)
744.10%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Argenx SE ARGX | 38.42B Large-cap | -1.07% | 11.60% | 35.45% | 11.72% | 3.34% | 31.86% | 71.29% | 177.33% |
| UCB S.A UCB | 39.10B Large-cap | 0.49% | 4.66% | 25.61% | 15.07% | 7.92% | 27.98% | 190.35% | 111.49% |
| Onward Medical N.V ONWD | 245.24M Mid-cap | 1.54% | 4.35% | 20.55% | 10.92% | -1.12% | 3.13% | -0.38% | -58.56% |
| Hyloris HYL | 177.52M Mid-cap | -3.23% | -10.45% | 1.35% | -3.85% | -6.25% | 5.63% | -53.92% | -40.94% |
| European Medical ALEMS | 21.80M Small-cap | 22.62% | 9.57% | 9.57% | -16.94% | -14.17% | -24.60% | -87.28% | -92.81% |
| Celyad Oncology S.A CYAD | 13.43M Small-cap | 3.33% | -22.50% | -22.50% | -46.55% | -53.73% | 14.81% | -79.19% | -96.23% |
Ownership & Short Interest
Insider Ownership
0.00%
Institutional Ownership
41.54%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
231K
Average 90-Day Volume
137K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ARGX's 52-week high and low?
- In the last 52 weeks, Argenx SE reached a high of €664.80 (on September 10, 2025) and a low of €456.30 (on September 24, 2024).
- What is the market cap and P/E ratio for ARGX?
- Curious about Argenx SE's size and valuation? Its market capitalization stands at 38.42B. When it comes to valuation, the P/E ratio (trailing twelve months) is 37.82, and the forward P/E (looking ahead) is 77.45.
- Does ARGX pay dividends? If so, what's the yield?
- As for dividends, Argenx SE isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Argenx SE's main competitors or similar companies to consider before investing?
When looking at Argenx SE, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return UCB S.A
UCB39.10B Healthcare Biotechnology 27.98% 190.35% Onward Medical N.V
ONWD245.24M Healthcare Biotechnology 3.13% -0.38% Hyloris
HYL177.52M Healthcare Biotechnology 5.63% -53.92% European Medical
ALEMS21.80M Healthcare Biotechnology -24.60% -87.28% Celyad Oncology S.A
CYAD13.43M Healthcare Biotechnology 14.81% -79.19% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Argenx SE? (e.g., ROE, Debt/Equity)
- To get a sense of Argenx SE's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 24.72%, the Debt to Equity ratio from the most recent quarter is 0.71, and its Gross Profit Margin stands at 88.32%.
- What is the recent revenue and earnings growth for ARGX?
- Looking at Argenx SE's growth, its revenue over the trailing twelve months (TTM) was €3B. Compared to the same quarter last year (YoY), quarterly revenue grew by 97.60%, and quarterly earnings saw a YoY growth of 744.10%.
- How much of ARGX stock is held by insiders and institutions?
- Wondering who owns Argenx SE stock? Company insiders (like executives and directors) hold about 0.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 41.54%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.